antibody

Epidermal Growth Factor Receptor, phosphorylated (Tyr1068) (erbB, EGFR)

E3375-53A

100 ul

polyclonal

domestic rabbit

nonconjugated

phosphorylated

Epidermal Growth Factor Receptor, phosphorylated (Tyr1068) (erbB, EGFR)

rabbit

Pab

Phosphorylated

Antibodies

100 ul

IgG

The epidermal growth factor (EGF) receptor is a 170kD transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling and lysosomal degradation. Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme and providing a binding surface for substrate proteins. c-Src is involved in phosphorylation of EGFR at Tyr845. The SH2 domain of PLCgamma binds at phospho-Tyr992, resulting in activation of PLCgamma-mediated downstream signaling. Phosphorylation of EGFR at Tyr1045 creates a major docking site for c-Cbl, an adaptor protein that leads to receptor ubiquitination and degradation following EGFR activation. The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068. A pair of phosphorylated residues (Tyr1148 and Tyr1173) provides a docking site for the SHC scaffold protein, with both sites involved in MAP kinase signaling activation. Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutation to either of these serines results in upregulated EGFR tyrosine autophosphorylation. Applications: Suitable for use in ELISA, Western Blot and Immunohistochemistry. Other applications have not been tested. Recommended Dilutions: Western Blot: 1:1000 Immunohistochemistry (Paraffin): 1:350 Use EDTA as the unmasking buffer. Dilute E3375-53A in TBST, 5% NGS. Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu Mo Rt

Synthetic phosphopeptide corresponding to residues surrounding Tyr1068 of human EGF receptor.

Recognizes endogenous levels of human EGF receptor at ~175kD only when phosphorylated at Tyr1068. May recognize other activated EGF receptor family members (ErbB2) and crossreacts slightly with activated PDGF receptor. Species Crossreactivity: mouse and rat

Purified by Protein A and peptide affinity chromatography.

Supplied as a liquid in 10mM HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. No preservative added.

Not Determined

Product Type: Pab Isotype: IgG Host: rabbit Source: human Concentration: Not Determined Form: Supplied as a liquid in 10mM HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol. No preservative added. Purity: Purified by Protein A and peptide affinity chromatography. Immunogen: Synthetic phosphopeptide corresponding to residues surrounding Tyr1068 of human EGF receptor. Specificity: Recognizes endogenous levels of human EGF receptor at ~175kD only when phosphorylated at Tyr1068. May recognize other activated EGF receptor family members (ErbB2) and crossreacts slightly with activated PDGF receptor. Species Crossreactivity: mouse and rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

E IHC WB

-20°C

1. Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9. 2. Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12. 3. Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-4. 4. Hubbard, S.R. et al. (1994) Nature 372, 746-54. 5. Biscardi, J.S. et al. (1999) J Biol Chem 274, 8335-43. 6. Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86. 7. Levkowitz, G. et al. (1999) Mol Cell 4, 1029-40. 8. Ettenberg, S.A. et al. (1999) Oncogene 18, 1855-66. 9. Rojas, M. et al. (1996) J Biol Chem 271, 27456-61. 10. Feinmesser, R.L. et al. (1999) J Biol Chem 274, 16168-73.

https://usbio-images.r.worldssl.net/prodimages/43/E3375-53A_1.jpg

IHC annalysis of paraffin-embedded MDA-MB-468 cells, untreated (left), EGF treated (middle), or EGF and Tarceva treated (right), using E3375-53A.